Researchers at Duke-NUS Medical School in Singapore have developed an intranasal COVID-19 vaccine that enhances the immune system’s response to the virus, providing longer-lasting, greater protection than vaccine injections, even against new and emerging variants. The novel vaccine candidate could mean fewer boosters in future.
The team from U.S. biotech firm Novelna wrote: “At stage I (the earliest cancer stage) and at the specificity of 99%, our panels were able to identify 93% of cancers among males and 84% of cancers among females.” It believes its cheaper, less invasive multi-cancer screening test could be a ‘gamechanger.’
A new Polish national program plans to replace half the country’s 2.7 million wood and coal-fired furnaces with natural gas furnaces or even more efficient heat pumps by 2030. The policy is projected to save more than 21,000 lives a year in Poland, increase the number of people breathing clean air 15-fold, and help Poland reach new E.U. air quality standards.
For many years, research has focused on identifying novel therapies that stimulate beta-cell growth and function to restore insulin production in type 1 diabetics. Now, researchers at the Baker Heart and Diabetes Institute in Melbourne have brought us a step closer to making this a reality, regenerating damaged pancreatic cells so they can produce insulin and functionally respond to blood glucose levels. The novel therapeutic approach has the potential to become the first disease-modifying treatment for type 1 diabetes.
Following promising results from this recent trail, the combination of Moderna’s new mRNA-4157 and KEYTRUDA has been granted Breakthrough Therapy Designation by the FDA in the U.S., and accepted into the Priority Medicines scheme by the European Medicines Agency, for the treatment of high-risk melanoma.
A new study from Australia’s Murdoch University evaluating the effectiveness of an eight-week program focusing on self-compassion and mindfulness found that it reduced symptoms of post-traumatic stress and improved quality of life and connectivity in parts of the brain that regulate emotions.
The discovery of a new compound that can kill a drug-resistant bacterium that kills thousands worldwide every year could prove to be a turning point in the fight against antibiotic resistance.
New research from Maryland-based Sunstone Therapies found that psilocybin-assisted therapy for cancer patients induced a clinically meaningful improvement in depression symptoms, with 80% of participants demonstrating a sustained response and 50% showing full remission of depression symptoms at week one, which was sustained for eight weeks.
A drug that targets the deadliest form of breast cancer was administered to 16 women in three separate doses in a trial conducted at the Cleveland Clinic with funding from the Pentagon. The trial found that the drug elicits no side effects and triggered an immune response in 75% of patients.
“We’ll make it clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House adviser Lael Brainard said on a press call.
